Bactericidal activity of ACH-702 against nondividing and biofilm staphylococci

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 7, 2012, Pages 3812-3818

  Podos, Steven D ^a   Thanassi, Jane A ^a   Leggio, Melissa ^a,b   Pucci, Michael J ^a  

^a Achillion Pharmaceuticals   (United States)

^b Rib X Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACH 702; ANTIINFECTIVE AGENT; ISOTHIAZOLOQUINOLONE; LINEZOLID; MOXIFLOXACIN; RIFAMPICIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ARTICLE; BACTERIAL CELL; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BIOFILM; CELL COUNT; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCACEAE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS;

ACETAMIDES; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BIOFILMS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; OXAZOLIDINONES; QUINOLINES; QUINOLONES; RIFAMPIN; STAPHYLOCOCCUS; THIAZOLES; VANCOMYCIN;

EID: 84862576650     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00092-12     Document Type: Article

References (43)

1. Anderson VE, Zaniewski RP, Kaczmarek FS, Gootz TD, Osheroff N. 2000. Action of quinolones against Staphylococcus aureus topoisomerase IV: basis for DNA cleavage enhancement. Biochemistry 39:2726-2732. (Pubitemid 30148927)
2. Belley A, at al. 2009. Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro. Antimicrob. Agents Chemother. 53: 918-925.
3. Chambers HF, Deleo FR. 2009. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat. Rev. Microbiol. 7:629-641.
4. Cheng J, et al. 2007. Dual targeting of gyrase and topoisomerase IV: target interactions of heteroaryl isothiazoloquinolones in Staphylococcus aureus. Antimicrob. Agents Chemother. 51:2445-2453. (Pubitemid 47047323)
5. Christensen GD, Baddour LM, Simpson WA. 1987. Phenotypic variation of Staphylococcus epidermidis slime production in vitro and in vivo. Infect. Immun. 55:2870-2877. (Pubitemid 18008251)
6. Chuard C, Vaudaux PF, Proctor RA, Lew DP. 1997. Decreased susceptibility to antibiotic killing of a stable small colony variant of Staphylococcus aureus in fluid phase and on fibronectin-coated surfaces. J. Antimicrob. Chemother. 39:603-608. (Pubitemid 27236878)
7. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. CLSI document M7-A7, 7th ed, vol 26, no. 2. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Croes S, Beisser PS, Neef C, Bruggeman CA, Stobberingh EE. 2010. Unpredictable effects of rifampin as an adjunctive agent in elimination of rifampin-susceptible and -resistant Staphylococcus aureus strains grown in biofilms. Antimicrob. Agents Chemother. 54:3907-3912.
9. Crumplin GC, Smith JT. 1975. Nalidixic acid: an antibacterial paradox. Antimicrob. Agents Chemother. 8:251-261.
10. Donlan RM. 2002. Biofilms: microbial life on surfaces. Emerg. Infect. Dis. 8:881-890. (Pubitemid 35000803)
11. Donlan RM, Costerton JW. 2002. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin. Microbiol. Rev. 15:167-193. (Pubitemid 34303762)
12. Drlica K, Malik M, Kerns RJ, Zhao X. 2008. Quinolone-mediated bacterial death. Antimicrob. Agents Chemother. 52:385-392. (Pubitemid 351170804)
13. Dwyer DJ, Kohanski MA, Hayete B, Collins JJ. 2007. Gyrase inhibitors induce an oxidative damage cellular death pathway in Escherichia coli. Mol. Syst. Biol. 3:91.
14. Eng RH, Padberg FT, Smith SM, Tan EN, Cherubin CE. 1991. Bactericidal effects of antibiotics on slowly growing and nongrowing bacteria. Antimicrob. Agents Chemother. 35:1824-1828.
15. Frank KL, Reichert EJ, Piper KE, Patel R. 2007. In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates. Antimicrob. Agents Chemother. 51:888-895. (Pubitemid 46355272)
16. Gradelski E, Kolek B, Bonner D, Fung-Tomc J. 2002. Bactericidal mechanism of gatifloxacin compared with other quinolones. J. Antimicrob. Chemother. 49:185-188. (Pubitemid 34100665)
17. Hall-Stoodley L, Costerton JW, Stoodley P. 2004. Bacterial biofilms: from the natural environment to infectious diseases. Nat. Rev. Microbiol. 2:95-108. (Pubitemid 39490064)
18. Hooper DC. 2002. Fluoroquinolone resistance among Gram-positive cocci. Lancet Infect. Dis. 2:530-538. (Pubitemid 34966356)
19. Hooper DC. 2000. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin. Infect. Dis. 2:S24-S28. (Pubitemid 32269605)
20. Ince D, Zhang X, Hooper DC. 2003. Activity of and resistance to moxifloxacin in Staphylococcus aureus. Antimicrob. Agents Chemother. 47: 1410-1415. (Pubitemid 36368607)
21. Ji G, Beavis RC, Novick RP. 1995. Cell density control of staphylococcal virulence mediated by an octapeptide pheromone. Proc. Natl. Acad. Sci. U. S. A. 92:12055-12059. (Pubitemid 26014010)
22. Khodursky AB, Cozzarelli NR. 1998. The mechanism of inhibition of topoisomerase IV by quinolone antibacterials. J. Biol. Chem. 273:27668-27677. (Pubitemid 28500492)
23. Lamp KC, Rybak MJ, Bailey EM, Kaatz GW. 1992. In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin. Antimicrob. Agents Chemother. 36:2709 -2714.
24. Larsson AJ, Walker KJ, Raddatz JK, Rotschafer JC. 1996. The concen-tration- independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions. J. Antimicrob. Chemother. 38:589-597. (Pubitemid 26390400)
25. Lynch AS, Robertson GT. 2008. Bacterial and fungal biofilm infections. Annu. Rev. Med. 59:415-428. (Pubitemid 351287946)
26. Malik M, Drlica K. 2006. Moxifloxacin lethality against Mycobacterium tuberculosis in the presence and absence of chloramphenicol. Antimicrob. Agents Chemother. 50:2842-2844. (Pubitemid 44198710)
27. Malik M, Zhao X, Drlica K. 2006. Lethal fragmentation of bacterial chromosomes mediated by DNA gyrase and quinolones. Mol. Microbiol. 61:810-825. (Pubitemid 44324102)
28. Malik M, et al. 2010. Effect of N-1/C-8 ring fusion and C-7 ring structure on fluoroquinolone lethality. Antimicrob. Agents Chemother. 54:5214-5221.
29. Malik J, et al. 2011. Fluoroquinolone and quinazolinedione activities against wild-type and gyrase mutant strains of Mycobacterium smegmatis. Antimicrob. Agents Chemother. 55:2335-2343.
30. Mascio CT, Alder JD, Silverman JA. 2007. Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells. Antimicrob. Agents Chemother. 51:4255-4260. (Pubitemid 350209874)
31. Mercier RC, Stumpo C, Rybak MJ. 2002. Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium. J. Antimicrob. Chemother. 50:19-24. (Pubitemid 34785250)
32. Murillo O, et al. 2009. Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicil-lin- resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53: 4252-4257.
33. Novick RP. 2000. Pathogenicity factors and their regulation, p 392-407. In Fischetti VA, Novick RP, Ferretti JJ, Portnoy DA, Rood JI (ed), Grampositive pathogens. ASM Press, Washington, DC.
34. Olson ME, Slater SR, Rupp ME, Fey PD. 2010. Rifampicin enhances activity of daptomycin and vancomycin against both a polysaccharide intercellular adhesin (PIA)-dependent and -independent Staphylococcus epidermidis biofilm. J. Antimicrob. Chemother. 65:2164-2171.
35. Ooi N, et al. 2010. XF-70 and XF-73, novel antibacterial agents active against slow-growing and non-dividing cultures of Staphylococcus aureus including biofilms. J. Antimicrob. Chemother. 65:72-78.
36. Pucci MJ, et al. 2007. In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens. Antimicrob. Agents Chemother. 51:1259-1267. (Pubitemid 46586803)
37. Pucci MJ, et al. 2011. In vitro and in vivo profile of ACH-702, an isothiazoloquinolone, against bacterial pathogens. Antimicrob. Agents Chemother. 55:2860-2871.
38. Tenover FC. 2006. Mechanisms of antimicrobial resistance in bacteria. Am. J. Med. 119(Suppl 1):S3-S10.
39. Villain-Guillot P, Gualtieri M, Bastide L, Leonetti JP. 2007. In vitro activities of different inhibitors of bacterial transcription against Staphylococcus epidermidis biofilm. Antimicrob. Agents Chemother. 51:3117-3121. (Pubitemid 350067517)
40. Vuong C, Saenz HL, Götz F, Otto M. 2000. Impact of the agr quorumsensing system on adherence to polystyrene in Staphylococcus aureus. J. Infect. Dis. 182:1688 -1693.
41. Wang Q, et al. 2007. Isothiazoloquinolones with enhanced antistaphylococcal activities against multidrug-resistant strains: effects of structural modifications at the 6-, 7-, and 8-positions. J. Med. Chem. 50 : 199 -210.
42. Wang X, Zhao X, Malik M, Drlica K. 2010. Contribution of reactive oxygen species to pathways of quinolone-mediated bacterial cell death. J. Antimicrob. Chemother. 65:520-524.
43. Zeiler HJ. 1985. Evaluation of the in vitro bactericidal action of ciprofloxacin on cells of Escherichia coli in the logarithmic and stationary-phase phases of growth. Antimicrob. Agents Chemother. 28:524-527.